Teva Launches Dollar and Euro Senior-Note Offering to Refinance Existing Debt

Teva Pharmaceutical Industries launched a new senior-note offering on Monday through three finance subsidiaries, with separate euro- and U.S.-dollar-denominated tranches intended primarily to refinance existing debt. The company did not announce the aggregate size, coupons or maturities of the new notes at launch, leaving the final economics subject to market conditions.

Teva’s stated use of proceeds centers on liability management rather than an announced operating investment program. Net proceeds, together with cash on hand, are expected to fund specified debt redemptions and related fees and expenses, with any remaining proceeds available for general corporate purposes, including additional debt repayment.

Offering proceeds are tied to five debt redemptions

In its September 7 offering announcement, Teva identified five existing note series that it intends to redeem if the new financing is completed. The planned redemptions cover all outstanding 6.750% senior notes due 2028, all outstanding 7.875% sustainability-linked senior notes due 2029 and all outstanding 7.375% sustainability-linked senior notes due 2029.

Teva also plans to redeem up to $450 million principal amount of its 4.750% sustainability-linked senior notes due 2027 and up to €1.25 billion principal amount of its 4.375% sustainability-linked senior notes due 2030. The company’s debt-securities schedule currently shows $649 million outstanding on the 4.750% 2027 notes and €1.5 billion outstanding on the 4.375% 2030 notes, so the announced caps would leave portions of those two series outstanding if Teva uses the full stated redemption amounts and makes no further changes.

The same debt schedule lists $1.25 billion outstanding on the 6.750% notes due 2028, $398 million on the 7.875% sustainability-linked notes due 2029 and €663 million on the 7.375% sustainability-linked notes due 2029. Those three series are slated for full redemption under the plan announced Monday. Teva said it can also issue additional conditional redemption notices or change the principal amounts targeted under the announced notices, subject to the applicable indentures, but it is not required to do so.

The announced list is selective rather than a complete refinancing of Teva’s near-term maturities. Its debt schedule also shows other notes due between 2026 and 2030 that are not among the five series named Monday, and the launch announcement did not explain why those particular obligations were chosen. The redemption notices are expected to depend on completion of the new note sale, while the offering itself is not conditioned on the redemptions. Net proceeds may also be invested temporarily before they are applied to the stated uses.

Teva is refinancing from a stronger credit position

The offering comes as Teva continues to reduce debt and only three days after it announced that S&P Global Ratings had raised its long-term issuer credit rating to BBB- from BB+, with a stable outlook. Teva said the S&P action, together with recent upgrades by Fitch and Moody’s, means the company now carries investment-grade ratings from all agencies that cover its debt.

That credit backdrop is relevant to the new financing, although the launch announcement does not establish what borrowing cost Teva will ultimately achieve. Final coupons, maturities and issue sizes will determine whether the refinancing lowers interest expense, extends the maturity profile, or primarily reshapes near- and medium-term obligations. Until pricing is announced, those effects cannot be quantified from the launch materials alone.

Teva reported $16.59 billion of total debt at June 30, 2026, down from $16.81 billion at the end of 2025. Cash and cash equivalents were $3.66 billion, leaving net debt of $12.94 billion. The company also said 27% of total debt was classified as short term at the end of June, compared with 11% at year-end, while its average debt maturity had shortened to about 5.1 years from 5.6 years.

Cash generation gives Teva another source of funding alongside the bond market. Second-quarter free cash flow was $622 million, up from $476 million a year earlier, and the company maintained a 2026 free-cash-flow outlook of $2.0 billion to $2.4 billion when it reported results in late July. Teva’s stated plan to pair offering proceeds with cash on hand therefore fits a broader effort to manage maturities without relying solely on newly issued debt.

The latest sale follows Teva’s 2025 refinancing

The structure also resembles a refinancing Teva carried out in May 2025. It initially launched a $2.0 billion-equivalent senior-note offering, then increased and priced the sale at about $2.3 billion equivalent. That financing included €1.0 billion of 4.125% notes due 2031, $500 million of 6.000% notes due 2032 and $700 million of 5.750% notes due 2030, with proceeds directed toward tender offers for older debt and related costs.

Monday’s launch again uses Teva Pharmaceutical Finance Netherlands II B.V. for the euro-denominated notes and Teva Pharmaceutical Finance Netherlands III B.V. and Teva Pharmaceutical Finance Netherlands IV B.V. for the dollar-denominated notes. The new securities will be unsecured senior obligations of the issuing subsidiaries and will be unconditionally guaranteed on a senior basis by Teva Pharmaceutical Industries.

Teva said the notes will be offered under its effective automatic shelf registration statement filed with the U.S. Securities and Exchange Commission in February 2025, through a prospectus supplement and accompanying base prospectus. The announcement names BNP Paribas, Citigroup, Goldman Sachs and J.P. Morgan entities among the banks through which investors can obtain offering materials.

What is still missing is the final size and pricing of the new debt. The launch gives a clear list of obligations Teva wants to retire, but the amount raised, the split between euro and dollar tranches, their maturities and their coupons remain to be set. If the sale proceeds, the next concrete disclosure should be the pricing and final terms, followed by completion of the offering and the conditional redemptions if Teva proceeds as announced.